162 related articles for article (PubMed ID: 36658786)
1. Management of adult patients with haematological malignancies in critical care.
Fizza Haider S; Sloss R; Jhanji S; Nicholson E; Creagh-Brown B
Anaesthesia; 2023 Jul; 78(7):874-883. PubMed ID: 36658786
[TBL] [Abstract][Full Text] [Related]
2. Hospital end-of-life care in haematological malignancies.
Beaussant Y; Daguindau E; Chauchet A; Rochigneux P; Tournigand C; Aubry R; Morin L
BMJ Support Palliat Care; 2018 Sep; 8(3):314-324. PubMed ID: 29434048
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
[TBL] [Abstract][Full Text] [Related]
4. Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors.
Evison J; Rickenbacher P; Ritz R; Gratwohl A; Haberthür C; Elsasser S; Passweg JR
Swiss Med Wkly; 2001 Dec; 131(47-48):681-6. PubMed ID: 11875752
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive approach to therapy of haematological malignancies in older patients.
Cordoba R; Eyre TA; Klepin HD; Wildes TM; Goede V
Lancet Haematol; 2021 Nov; 8(11):e840-e852. PubMed ID: 34624238
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
7. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies.
Ikezoe T
Int J Hematol; 2021 Jan; 113(1):34-44. PubMed ID: 32902759
[TBL] [Abstract][Full Text] [Related]
8. [Critical care of Onco-hematology patients: new therapeutic targets, new complications and new admission policies].
Lengline E; Darmon M; Azoulay E; Le Gall JR
Bull Acad Natl Med; 2015; 199(2-3):293-312. PubMed ID: 27476311
[TBL] [Abstract][Full Text] [Related]
9. The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study.
von Felden J; Alric L; Pischke S; Aitken C; Schlabe S; Spengler U; Giordani MT; Schnitzler P; Bettinger D; Thimme R; Xhaard A; Binder M; Ayuk F; Lohse AW; Cornelissen JJ; de Man RA; Mallet V
J Hepatol; 2019 Sep; 71(3):465-472. PubMed ID: 31108159
[TBL] [Abstract][Full Text] [Related]
10. Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
[TBL] [Abstract][Full Text] [Related]
11. Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies.
Benoit DD; Hoste EA; Depuydt PO; Offner FC; Lameire NH; Vandewoude KH; Dhondt AW; Noens LA; Decruyenaere JM
Nephrol Dial Transplant; 2005 Mar; 20(3):552-8. PubMed ID: 15671075
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland.
Tiihonen J; Tanskanen A; Bell JS; Dawson JL; Kataja V; Taipale H
Lancet Psychiatry; 2022 May; 9(5):353-362. PubMed ID: 35334224
[TBL] [Abstract][Full Text] [Related]
13. [Patients with a haematological malignancy in intensive care].
van de Ven M; Silderhuis VM; Brouwer RM; Legdeur MC; Smit WM
Ned Tijdschr Geneeskd; 2009; 153():A582. PubMed ID: 19930742
[TBL] [Abstract][Full Text] [Related]
14. Kidney diseases associated with haematological cancers.
Ganguli A; Sawinski D; Berns JS
Nat Rev Nephrol; 2015 Aug; 11(8):478-90. PubMed ID: 26035773
[TBL] [Abstract][Full Text] [Related]
15. How many patients with haematological malignancy need the facilities offered by a district general hospital?
Low J; Smith A; George S; Roderick P; Davis C
J Public Health Med; 2002 Sep; 24(3):196-9. PubMed ID: 12831089
[TBL] [Abstract][Full Text] [Related]
16. Intensive care for patients with medical complications of haematological malignancy: is it worth it?
Hinds CJ; Martin R; Quinton P
Schweiz Med Wochenschr; 1998 Sep; 128(39):1467-73. PubMed ID: 9793166
[TBL] [Abstract][Full Text] [Related]
17. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
18. Palliative home care for patients with advanced haematological malignancies-a multicenter survey.
Kaiser F; Rudloff LV; Vehling-Kaiser U; Hollburg W; Nauck F; Alt-Epping B
Ann Hematol; 2017 Sep; 96(9):1557-1562. PubMed ID: 28638954
[TBL] [Abstract][Full Text] [Related]
19. Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective.
Gutierrez C; McEvoy C; Mead E; Stephens RS; Munshi L; Detsky ME; Pastores SM; Nates JL
Crit Care Med; 2018 Sep; 46(9):1402-1410. PubMed ID: 29939878
[TBL] [Abstract][Full Text] [Related]
20. Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case-control study.
Oliva A; Curtolo A; Volpicelli L; Cancelli F; Borrazzo C; Cogliati Dezza F; Marcelli G; Gavaruzzi F; Di Bari S; Ricci P; Turriziani O; Mastroianni CM; Venditti M
Infection; 2022 Oct; 50(5):1373-1382. PubMed ID: 35781785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
